Autologous Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Antibody Mediated Kidney Graft Rejection (ABMR)
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Enrollment
- 4
- Locations
- 2
- Primary Endpoint
- Safety of MSC transplantation as assessed by adverse events according to CTCAE Version 5Estimated glomerular filtration rate (eGFR)
Study Overview
Brief Summary
Transplant rejection is one of the biggest limitations in renal transplant procedures, where the kidney can undergo an acute, late acute, or chronic transplant rejection. With the advancement in transplantation protocols, acute survival of renal transplants has improved, but long-term survival is still unsatisfactory, as most of the renal transplants develop chronic graft rejection. Unfortunately, there is little the investigators know when it comes to improving long-term survival of renal transplants. Mesenchymal stem cells (MSC) have been shown to have immunosuppressive and repairing properties. The purpose of this study is to find out whether MSC in combination with standard therapy of antibody mediated rejection (ABMR) are more effective in preventing organ deterioration and maintaining kidney function.
Detailed Description
Participants will be assigned to receive the full immunosuppressive therapy indicated to treat chronic ABMR (including plasmapheresis (PF) 7x, intravenous immune globulins 100 mg/kg 7x, corticosteroid) and MSC infusions (2x106cells/kg bw after PF) (Group 1) and be compared to historic controls according to "propensity score matching" (treated with immunosuppressive therapy alone (Group 2)). Patients will undergo MSC infusions at the start of the study after each PF. One year post- infusions, patients will be evaluated and undergo kidney biopsies. Blood collection will occur at regular intervals, serum creatinine and the estimated creatinine clearance will be monthly recorded. The transplanted kidney function and morphology (US Doppler) will be evaluated.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Recipients of a renal allograft, male and female patients age >18
- •The eGF>20 ml/min/1.73 m2,
- •Renal biopsy Criteria: chronic active ABMR.
- •Written informed consent, compliant with local regulations.
Exclusion Criteria
- •Recipients of multiple organs.
- •Pregnant women.
- •Malignant disease in last 5 years
- •Active autoimmune disease
- •Active infection including hepatitis B, hepatitis C, HIV, or tuberculosis
- •Evidence of congestive cardiac failure and/or acute coronary syndrome in past 6 months.
- •Evidence of liver disease
- •Inadequate compliance to treatment.
Arms & Interventions
Historic control
historic cohort of patients with ABMR treated with standard of care therapy
MSC transplantation
patients with ABMR treated with MSC transplantation
Intervention: MSC transplantation (Other)
Outcomes
Primary Outcomes
Safety of MSC transplantation as assessed by adverse events according to CTCAE Version 5Estimated glomerular filtration rate (eGFR)
Time Frame: 12 months
Adverse events according to CTCAE Version 5
Secondary Outcomes
- Estimated glomerular filtration rate (eGFR)(12 months)
- Graft survival rate(12 months)
Investigators
Veceric-Haler Zeljka
Principal investigator
University Medical Centre Ljubljana